Humanized anti-VEGF monoclonal antibodies, like bevacizumab (Avastin(r)), which was approved by the FDA in February 2004, or ranibizumab (Lucentis(r)), have proven their effectiveness in some cancers, but still not in osteosarcoma. Here, VEGFA is linked to cancer.